ARTIMPLANT THREE - MONTH REPORT 2012

  · Net revenue amounted to SEK 6.8 million (5.4), an increase of 27
percentage points.
  · The net loss totaled SEK 2.3 million (3.9).  
  ·
Earnings per stock unit amounted to SEK -0.01 (-0.03).
  · The result has
improved by SEK 1.6 million compared to the corresponding period last year.
  ·
Positive sales trend on all markets. Own sales in the USA increased by 86
percentage points and in Europe by 42 percentage points.
  · A new stock issue
during the first quarter generated capital input for the Company of SEK 23.7
million before issue costs.

Events after the period-end

  · The agreement
with Biomet was terminated in April.

* Figures in brackets refer to the
corresponding period last year.

 N. B. This is a translation from Swedish.
The Swedish version shall always take precedence.

 

For further
information, please contact:

Kjell Thörnbring, CEO
E-mail:
kjell.thornbring@artimplant.com
Telephone:  +46 703 11 90 25

Further
information at www.artimplant.com where one also can subscribe to future press
releases; www.artimplant.com/investors-media/subscribe-to-press
-releases.html

Artimplant
Artimplant is a biomaterials company focused on
solutions to problems in orthopedic. We restore health through the development,
production and marketing of degradable implants that regenerate body functions
and improve quality of life. Our products, made from Artelon®, meet unmet
clinical needs and are marketed in a growing number of therapy areas. Artimplant
produces implants for treatment of osteoarthritis in hands and feet, for
shoulder and other soft tissue injuries.

Artimplant is a public company
listed on the OMX Nordic Exchange Stockholm in the Small Cap segment and in the
healthcare sector.

Forward-looking statements
This press release contains
forward-looking statements as defined in the U.S. Private Securities Litigation
Reform Act of 1995. Readers are cautioned not to place undue reliance on these
forward-looking statements. Actual results may differ materially from those
indicated by these forward-looking statements as a result of risks and
uncertainties impacting the Company's business including increased competition;
the ability of the Company to expand its operations and to attract and retain
qualified professionals; technological obsolescence; general economic
conditions; and other risks detailed from time to time in the Company's
filings.

This is information which Artimplant shall make public pursuant to
the Swedish Financial Instruments Act and the Swedish Securities Exchange and
Clearing Operations Act and/or stock market agreements. Information was made
available for publication on May 3, 2012 at 3 PM (Swedish time).